DWP216 / Daewoong Pharma - LARVOL DELTA

DWP216, a novel TEAD1 selective inhibitor for NF2 mutant tumors and drug-tolerant persister cells (AACR 2025) - "In conclusion, DWP216 is a promising TEAD1 selective inhibitor for NF2 mutant tumor and may be a proper option for drug-resistance of targeted therapy. DWP216 is preparing toward to IND filing for Phase 1 in 2025."

Brain Cancer • CNS Tumor • Meningioma • Mesothelioma • Oncology • Solid Tumor • KRAS • NF2 • TEAD1 • YAP1

Daewoong Pharmaceutical to unveil 3 anticancer pipelines at AACR 2025 (Korea Biomedical Review) - "Daewoong Pharmaceutical, a Korean drugmaker, said on Friday that it will unveil three anticancer pipelines at the 2025 American Association for Cancer Research (AACR) annual meeting, taking place from April 25 to 30 in Chicago, the U.S. The three investigational drugs are targeted therapy DWP216, immunotherapy DWP217, and synthetic lethality drug DWP223....Daewoong will showcase preclinical results of these three candidate drugs in four posters....DWP216 reduced cancer cell resistance and enhanced the effectiveness of existing anticancer drugs in non-small cell lung cancer and pancreatic cancer with EGFR and KRAS mutations. DWP217, the immunotherapy, proved more effective than current arginase inhibitors in animal studies, improving the immunosuppressive tumor environment and enabling immune cells to attack cancer more aggressively. DWP223, the synthetic lethality drug, showed potent anti-cancer effects at low doses in animal studies."

Preclinical • Non Small Cell Lung Cancer

Daewoong Pharmaceutical, Anticancer Drug Candidate ’DW216’ Selected for National New Drug Development Project∙∙∙Full-scale Promotion of High-Efficacy Anticancer Drug Development [Google translation] (BioTimes) - "Daewoong Pharmaceutical...announced on the 13th that its anticancer drug candidate 'DWP216' was selected as a project for the '2024 2nd National New Drug Development Project' hosted by the Korea Drug Development Fund. With this selection, Daewoong Pharmaceutical will receive research funding for non-clinical trials over the next two years. It plans to fully pursue the development of a highly effective anticancer drug targeting TEAD1....DWP216 is expected to be an important treatment option for cancers such as mesothelioma and brain tumors caused by NF2 mutations, and non-small cell lung cancer and pancreatic cancer where the effect of existing anticancer drugs is limited....Daewoong Pharmaceutical plans to verify the safety of DWP216, aiming to enter phase 1 clinical trials by 2026."

Financing • New P1 trial • Brain Cancer • Mesothelioma • Non Small Cell Lung Cancer • Pancreatic Cancer